PMC5287964_01
Response of a subcutaneous metastatic lesion to nivolumab, by week of treatment.
medi-96-e5951-g001.jpg
PMC5287964_01_medi-96-e5951-g001.jpg
F1
One week after the first cycle of nivolumab, a subcutaneous lesion in her upper back grew substantially, accompanied by severe pain and significant inflammatory reaction (Fig. 1). The subcutaneous lesions started to regress too, with complete resolution by the 12th week as well as improvement in all bone lesions (Figs. 1 and 2).
(A) PET-CT demonstrating a subcutaneous metastatic lesion, 2 months after starting nivolumab treatment (03/2015). (B) PET-CT demonstrating complete resolution of the lesion 5 months after starting nivolumab treatment (06/2015).
medi-96-e5951-g002.jpg
PMC5287964_01_medi-96-e5951-g002.jpg
F2
The subcutaneous lesions started to regress too, with complete resolution by the 12th week as well as improvement in all bone lesions (Figs. 1 and 2).